In Re John M. Corkill

771 F.2d 1496, 226 U.S.P.Q. (BNA) 1005, 1985 U.S. App. LEXIS 15257
CourtCourt of Appeals for the Federal Circuit
DecidedAugust 27, 1985
DocketAppeal 84-1683, 84-1684
StatusPublished
Cited by28 cases

This text of 771 F.2d 1496 (In Re John M. Corkill) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re John M. Corkill, 771 F.2d 1496, 226 U.S.P.Q. (BNA) 1005, 1985 U.S. App. LEXIS 15257 (Fed. Cir. 1985).

Opinion

PAULINE NEWMAN, Circuit Judge.

These consolidated appeals are from the decisions of the Patent and Trademark Office (PTO) Board of Appeals (the Board) sustaining the examiner’s rejection of claims 2-11, 13-28, 35-42, 49-58, 60-62, 64-74, and 77-79 in patent application Serial No. 450,266 as unpatentable for obviousness under 35 U.S.C. § 103; and the rejection of claims 1, 3-11, 16, 18, 19 and 21-28 in Serial No. 036,615 as unpatentable under 35 U.S.C. §§ 103 and 112. Serial No. 036,615 is a continuation of Serial No. 450,-266, and differs only in the claimed particle size ranges. Both are the invention of John M. Corkill, Bryan L. Madison, and Michael E. Burns (hereinafter collectively Corkill) and are entitled “Detergent Compositions”. We affirm in part and reverse in part.

OPINION

In both the ’266 and ’615 patent applications, Corkill claims the combination of certain zeolites with known detergents, to produce detergent compositions. Some of Cor-kill’s claims require as an additional component “an auxiliary detergent builder salt”.

The Board in a first set of appeals affirmed the rejections of the claims of both applications under section 103 but, except as discussed for the ’615 application, reversed the rejections under section 112. Further prosecution ensued, and in a second appeal the Board affirmed the rejections of all claims. The principal references relied on by the Board were U.S. Patent 3,661,789 to Corey et al. and U.S. Patent 2,882,243 to Milton, although a large number of additional references were cited during the course of an extended prosecution.

The §103 Rejection

We consider first the section 103 rejections as applied to those claims of both applications that are not restricted to the presence of an “auxiliary builder” in the composition. Claim 79 of the ’266 application is typical:

79. A detergent composition capable of rapidly reducing the free polyvalent metal ion content of an aqueous solution, comprising:
(a) from about 5% to about 95% by weight of a water-insoluble crystalline aluminosilicate ion exchange material of the formula
Naz[(A102)z.(Si02)y] X H20 wherein z and y are integers of at least 6; the molar ratio of z to y is in the range from 1.0 to about 0.5, and x is an integer from about 15 to 264; said aluminosilicate ion exchange material having a particle size diameter from about 0.1 micron to about 10 microns; a calcium ion exchange capacity on an anhydrous basis of at least about 200 milligrams equivalent of CaC03 hardness/gram; and a calcium ion exchange rate on an anhydrous basis of at least about 2 grains/gallon/minute gram; and
(b) from about 5% to about 95% by weight of a water-soluble organic surface-active agent selected from the group consisting of anionic, nonionic, ampholytic and zwitterionic surface-active agents and mixtures thereof.

The core of the board’s decision is that it would have been obvious to use known hydrated zeolites with known detergents to reduce water hardness, in view of Corey’s teaching of the use of hydrated zeolites with known detergents and bleach to reduce water hardness, and Milton’s teaching of zeolites having the same composition and properties as the zeolites in Corkill’s claims. Other references were also relied on, but we agree with the PTO that a prima facie case is made by the teachings and suggestions of these two references.

*1498 The Corey patent contains the following text:

[T]he detergents can be used in combination with the water-soluble soaps and water conditioners. The term “water conditioner” ... designates those compounds which sequester, or inactivate water hardness and aid in cleaning ... Illustrative of the inorganic water conditioners useful in the present invention are the zeolites (hydrated silicates of aluminum and either sodium or calcium or both), sodium carbonate, sodium phosphate, sodium acid phosphate, tetrasodium pyrophosphate, sodium tripolyphosphate, trisodium phosphate, sodium meta-phosphate, sodium hexametaphosphate, and sodium tetraphosphate. While the sodium salts of the inorganic compounds are preferred, the other alkali metal salts such as the potassium and lithium salts may be used, (column 4, lines 32-57)

Corkill criticizes the Corey disclosure as “filler”, and charges that Corey copied this disclosure from the text of some other patent. Corkill also asserts that Corey does not show that zeolites inactivate water hardness at a rate sufficiently rapid to enable zeolites to be used as replacements for phosphates in detergent compositions. Corkill argues that Corey “merely acknowledges the known art that suggested natural zeolites such as clays ... or, possibly, amorphous (non-crystalline) zeolites as detergent builders or extenders”, and that Corey contains no suggestion to use synthetic crystalline zeolites. Corkill also argues that Corey’s reference to calcium zeolites, necessarily inoperative to absorb calcium, shows the inadequacy of Corey as a reliable reference.

The PTO discounts the “filler” argument, correctly in our view, for Corey’s plain teaching of zeolites as sequestering agents in detergent compositions exists, whether or not Corey viewed it as “filler”. The Solicitor states that the reference to calcium is an obvious mistake, an issue we need not reach, for the Solicitor correctly observes that Corey states that the sodium salts are preferred, and the sodium salts are the subject of Corkill’s claims.

The PTO admits, as it must, that Corey does not state whether his hydrated zeolites are naturally occurring or synthetic, but the PTO takes issue with Corkill’s argument that Corey necessarily excluded the synthetic zeolites, observing that synthetic zeolites were well known — viz. those disclosed in Milton ten years prior to Corey’s filing date. Corkill, bearing the burden of coming forward, did not have persuasive support for his argument that Corey must be limited to the naturally occurring zeolites. We must agree with the PTO that Corey’s plain teaching is not limited to natural zeolites.

The PTO completed the foundation of its prima facie case with the Milton reference, which shows hydrated and dehydrated zeolite A. The PTO points out that the claimed limitations to Corkill’s zeolites relating to hydration, particle size, and sequestering action, are all properties of Milton’s zeolites.

Corkill argues that Milton did not recognize that sufficiently rapid sequestration could be obtained. The Milton data show hydrated sodium zeolite A (a zeolite preferred by Corkill) exchanging calcium ions over a period of several days, but Milton also states:

The rate of exchange of sodium zeolite A can under some conditions be quite rapid. For instance, when sodium zeolite A was put into a solution 0.1 molar in calcium ions, 47% of the sodium ions were replaced in a two minute contact time at 25°C and in 7Va minutes the exchange was 59% complete.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

BTG Int'l Ltd. v. Amneal Pharm. LLC
352 F. Supp. 3d 352 (D. New Jersey, 2018)
Ucb, Inc. v. Accord Healthcare, Inc.
890 F.3d 1313 (Federal Circuit, 2018)
Boston Scientific Corp. v. Johnson & Johnson Inc.
679 F. Supp. 2d 539 (D. Delaware, 2010)
Daiichi Sankyo Co. v. Mylan Pharmaceuticals Inc.
670 F. Supp. 2d 359 (D. New Jersey, 2009)
Procter & Gamble Co. v. Teva Pharmaceuticals USA, Inc.
566 F.3d 989 (Federal Circuit, 2009)
Boston Scientific Scimed, Inc. v. Cordis Corp.
554 F.3d 982 (Federal Circuit, 2009)
Pfizer v. Apotex (Formerly Known as Torpharm)
488 F.3d 1377 (Federal Circuit, 2007)
Pfizer, Inc. v. Apotex, Inc.
480 F.3d 1348 (Federal Circuit, 2007)
Exxon Research & Engineering Co. v. United States
46 Fed. Cl. 278 (Federal Claims, 2000)
In Re Richard P. Andros, Jr
988 F.2d 131 (Federal Circuit, 1993)
In Re Hans Oetiker
977 F.2d 1443 (Federal Circuit, 1992)
Standard Manufacturing Co. v. United States
25 Cl. Ct. 1 (Court of Claims, 1991)
General Electric Co. v. Hoechst Celanese Corp.
740 F. Supp. 305 (D. Delaware, 1990)
Merck & Co., Inc. v. Biocraft Laboratories, Inc.
874 F.2d 804 (Federal Circuit, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
771 F.2d 1496, 226 U.S.P.Q. (BNA) 1005, 1985 U.S. App. LEXIS 15257, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-john-m-corkill-cafc-1985.